Nanospot.ai Inc, producer of disruptive digital agglutination-based antibody tests, and Opto Immunosensors, pioneer provider of Connected Diagnostics, announced today that they have entered into a commercial distribution agreement for NanoSpot.ai’s SARS-CoV-2 Total Antibody Test. This agreement followed a pre-clinical study jointly performed in Athens, Greece, which verified the NanoSpot.ai technology platform. As a result, Opto becomes the first commercial partner of Nanospot.ai globally to launch its first product in Greece as a test-bed market.
The NanoSpot.ai SARS-CoV-2 Total Antibody Test uses an agglutination-based method combined with an artificial-intelligence driven mobile application to deliver semi-quantitative antibody results at the Point of Care. This unique approach enables accurate (98.0% sensitivity and 100% specificity) diagnostic results without the need for laboratory equipment in under 3 minutes sample-to-answer. The NanoSpot.ai SARS-CoV-2 Total Antibody Test has been CE-Marked.
Over the coming months, the two companies will be continuing their close collaboration to introduce the product to the public and support the adoption of its use as a first-line diagnostic tool in the field, not only in Greece and other countries outside the United States.